Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Status:
Completed
Trial end date:
2015-07-31
Target enrollment:
Participant gender:
Summary
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon
alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV)
Dual regimen (= Daclatasvir + Asunaprevir) and followed for an additional 24 weeks
post-treatment in order to determine the safety and efficacy of the DCV DUAL regimen